Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
Grosser T, Fries S, FitzGerald GA (2005)
Journal of Clinical Investigation 116(1): 4-15.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Grosser, TiloUniBi
;
Fries, Susanne;
FitzGerald, Garret A.
![](https://pub.uni-bielefeld.de/images/icon_orcid.png)
Abstract / Bemerkung
Inhibitors selective for prostaglandin G/H synthase-2 (PGHS-2) (known colloquially as COX-2) were designed to minimize gastrointestinal complications of traditional NSAIDs — adverse effects attributed to suppression of COX-1–derived PGE2 and prostacyclin (PGI2). Evidence from 2 randomized controlled-outcome trials (RCTs) of 2 structurally distinct selective inhibitors of COX-2 supports this hypothesis. However, 5 RCTs of 3 structurally distinct inhibitors also indicate that such compounds elevate the risk of myocardial infarction and stroke. The clinical information is biologically plausible, as it is compatible with evidence that inhibition of COX-2–derived PGI2 removes a protective constraint on thrombogenesis, hypertension, and atherogenesis in vivo. However, the concept of simply tipping a “balance” between COX-2–derived PGI2 and COX-1–derived platelet thromboxane is misplaced. Among the questions that remain to be addressed are the following: (a) whether this hazard extends to all or some of the traditional NSAIDs; (b) whether adjuvant therapies, such as low-dose aspirin, will mitigate the hazard and if so, at what cost; (c) whether COX-2 inhibitors result in cardiovascular risk transformation during chronic dosing; and (d) how we might identify individuals most likely to benefit or suffer from such drugs in the future.
Erscheinungsjahr
2005
Zeitschriftentitel
Journal of Clinical Investigation
Band
116
Ausgabe
1
Seite(n)
4-15
ISSN
0021-9738
Page URI
https://pub.uni-bielefeld.de/record/2965346
Zitieren
Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. Journal of Clinical Investigation. 2005;116(1):4-15.
Grosser, T., Fries, S., & FitzGerald , G. A. (2005). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. Journal of Clinical Investigation, 116(1), 4-15. https://doi.org/10.1172/JCI27291
Grosser, Tilo, Fries, Susanne, and FitzGerald , Garret A. 2005. “Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities”. Journal of Clinical Investigation 116 (1): 4-15.
Grosser, T., Fries, S., and FitzGerald , G. A. (2005). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. Journal of Clinical Investigation 116, 4-15.
Grosser, T., Fries, S., & FitzGerald , G.A., 2005. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. Journal of Clinical Investigation, 116(1), p 4-15.
T. Grosser, S. Fries, and G.A. FitzGerald, “Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities”, Journal of Clinical Investigation, vol. 116, 2005, pp. 4-15.
Grosser, T., Fries, S., FitzGerald , G.A.: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. Journal of Clinical Investigation. 116, 4-15 (2005).
Grosser, Tilo, Fries, Susanne, and FitzGerald , Garret A. “Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities”. Journal of Clinical Investigation 116.1 (2005): 4-15.
Daten bereitgestellt von European Bioinformatics Institute (EBI)
Zitationen in Europe PMC
Daten bereitgestellt von Europe PubMed Central.
References
Daten bereitgestellt von Europe PubMed Central.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Quellen
PMID: 16395396
PubMed | Europe PMC
Suchen in